Microbix announces that it expects to file the financial statements, management disclosure and analysis, and results news release for its second quarter of fiscal 2025 ended March 31, 2025 (“Q2 2025”) prior to the start of trading on May 15, 2025.

Microbix announces that its funding and commercialization partner, Sequel Pharma, LLC (“Sequel”), has executed an agreement with a leading international contract development and manufacturing organization (“CDMO”) for production of the formulated and packaged drug (i.e., “Drug Product”) of Kinlytic® urokinase (“Kinlytic”), a biologic drug for dissolving blood clots.

announces it will be attending and presenting at the 2025 Bloom Burton & Co. Healthcare Investor Conference (the “Conference”) taking place at the Metro Toronto Convention Centre, North Building, on Monday and Tuesday, May 5 & 6, 2025.

announces that it will be attending and exhibiting at ESCMID Global 2025 and that a customer and collaborator will be presenting results of a pilot External Quality Assessment (EQA) program enabled by Microbix Quality Assessment Products (QAPs™).

provides an update on U.S. and reciprocal tariff outcomes as well as business conditions and its outlook for the balance of its fiscal 2025.

announces the voting results from the Annual and Special Meeting of Shareholders of the Company (the “Meeting”) which was held on March 26, 2025.

announces the further optimization of the structure and utilization of its capital via the repayment of mortgage debt and expansion of its bank line of credit – Moves that reduce interest expenses while maintaining strategic flexibility and resilience.

announce that they have signed a Memorandum Of Understanding (MOU) under which Microbix will supply its PROCEEDx™FLOQ® brand Quality Assessment Products (QAPs™) to support quality management of testing for high-risk Human Papillomavirus (HPV) infections, which cause most cases of cervical cancer.

was pleased to host Government of Ontario candidates Premier Doug Ford (Etobicoke North riding) and local MPP Deepak Anand (Mississauga-Malton riding). During their site visit on the morning of February 27 — Ontario’s Provincial Election Day — our team had great conversations about how next-generation diagnostic tests can improve health outcomes for patients while also reducing healthcare costs.

announces the issuance of stock options under its shareholder-approved stock option plan (the “Stock Option Plan”), as part of its compensation programs to incentivize and retain its board of directors, executives, and managers.